spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  ADHD  

 HSMN NewsFeed - 31 Aug 2023
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 3 Nov 2022
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 2 May 2022
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Oct 2021
Tris Pharma(R) Hires Seasoned Business Development Executive
Biopharmaceuticals Generics Personnel
 HSMN NewsFeed - 21 Jul 2021
Corium Launches Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older
Biopharmaceutical Neurology Product Launch
 HSMN NewsFeed - 14 Jun 2021
KT and NeuroSigma Announce Strategic Digital Health Partnership
Devices
 HSMN NewsFeed - 13 May 2020
Arbor Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application (NDA) for AR19, an Investigational ADHD Prescription Stimulant Treatment Specifically Designed to Resist Physical Manipulation for Nonmedical Misuse or Abuse
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Oct 2019
Teijin and NeuroSigma Enter into Exclusive License Agreement
Devices Neurology Licensing
 HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Mar 2019
ANI Pharmaceuticals Announces Two Generic Product Launches
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 10 Oct 2018
Tris Pharma Announces Hiring of Chief Commercial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 7 Sep 2018
BDD Pharma and Cingulate Therapeutics Announce License Agreement With OralogiK(TM) Enabled Triple Pulse Products
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 31 May 2018
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 30 Oct 2017
UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD
Devices Neurology
 HSMN NewsFeed - 10 Aug 2017
Aevi Genomic Medicine Announces Agreement for $28 Million Private Placement
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Jul 2017
Cingulate Therapeutics Appoints Strategic Finance Veteran Louis G. Van Horn as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2017
Alcobra Announces Leadership Update
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2017
Supernus Receives Final FDA Approval for Trokendi XR(R) for Migraine Prophylaxis in Adults and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2017
Supernus Announces Settlement with Zydus on Trokendi XR(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Mar 2017
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 13 Dec 2016
Supernus Wins Appeal Case on Oxtellar XR(R)
Biopharmaceuticals Neurology Litigation
 HSMN NewsFeed - 28 Jul 2016
FDA Clears Expanded Indication for Itamar Medical's WatchPAT(TM) Sleep Apnea Diagnostic Device for Adolescents
Devices Diagnostics FDA
 HSMN NewsFeed - 16 May 2016
Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 17 Feb 2016
Impax Receives FDA Approval for Generic Version of Adderall XR(R) (mixed salts of a single-entity amphetamine product) Capsules, CII
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 10 Feb 2016
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Feb 2016
Supernus Prevails in Oxtellar XR(R) ANDA Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Feb 2016
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 28 Jan 2016
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients 6 Years and Older
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 29 Dec 2015
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
Devices Regenerative Medicine Dermatology FDA
 HSMN NewsFeed - 16 Nov 2015
NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD
Devices Neurology Regulatory
 HSMN NewsFeed - 21 May 2015
Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel(TM) XR
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 8 Jul 2014
Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden
Devices Neurology
 HSMN NewsFeed - 3 Jun 2014
Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President
Devices Neurology Personnel
 HSMN NewsFeed - 28 Mar 2014
NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives
Devices Neurology Personnel
 HSMN NewsFeed - 4 Mar 2014
Neos Therapeutics Completes $15.5 Million Additional Series C Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 25 Feb 2014
David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President
Devices Neurology Personnel
 HSMN NewsFeed - 11 Feb 2014
Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller
Devices Neurology Personnel
 HSMN NewsFeed - 27 Jan 2014
Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer
Devices Neurology Personnel
 HSMN NewsFeed - 13 Jan 2014
KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 25 Dec 2013
Supernus Announces Resignation of Board Member
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 22 Oct 2013
Neos Therapeutics, Inc. Announces the Appointment of Vipin K. Garg, Ph.D. as Chief Executive Officer and Board Director
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 19 Aug 2013
Supernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
Biopharmaceuticals Neurology FDA Product Launch
 HSMN NewsFeed - 7 Aug 2013
Supernus Sues Watson for Infringement of Oxtellar XR(TM) Patents
Biopharmaceuticals Generics Neurology Litigation
 HSMN NewsFeed - 30 Jul 2013
Alcobra Ltd. Appoints Dr. Jonathan Rubin as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2013
Tris Pharma's Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 22 Oct 2012
Pfizer To Acquire NextWave Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Oct 2012
Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 20 Jul 2012
Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2012
AssureRx Health Raises $12.5 Million Series C Financing
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 18 Nov 2011
Shire Announces Strategic Partnership for ADHD Medicines in Japan With Shionogi & Co., Ltd.
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2011
FDA Approves INTUNIV(R) (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2011
NextWave Pharmaceuticals Secures $45 Million in Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Nov 2010
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 Mar 2010
Cortex Sells Selected AMPAKINE Compounds and Rights to Respiratory Depression Indication to Biovail
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Jan 2010
Antares Pharma Expands Executive Team and Appoints Pavan Handa as Senior Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2009
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2009
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2009
Sciele Pharma and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel Used in Combination with Stimulants to Treat ADHD
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2009
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2009
Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 19 Mar 2009
Cortex Pharmaceuticals Announces Corporate Restructuring and Workforce Reduction
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2009
UCB to divest Equasym(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 7 Oct 2008
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2008
deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Aug 2008
Noven Provides Update on Daytrana(R) Methylphenidate Transdermal System
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jul 2008
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Biopharmaceuticals
 HSMN NewsFeed - 3 Jul 2008
Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Jul 2008
Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2008
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 May 2008
Cortex Pharmaceuticals Announces Management Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 May 2008
FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2008
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2008
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Mar 2008
Auriga Laboratories Announces FDA Approval of Liquadd(TM) (Dextroamphetamine Sulfate) Oral Solution for the Treatment of ADHD and Upcoming Product Launch
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2008
Cortex Receives Approval from German Regulatory Authority to Proceed with Two Clinical Trials for AMPAKINE(R) CX717 for the Acute Treatment of Respiratory Depression Due to Opiate Analgesics
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
Shire Announces Further Expansion Into Latin America
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2007
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2007
David Mott Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Oct 2007
New Therapies Emerging to Challenge Pain Management for Transdermal Patch Growth
Drug Delivery Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2007
Sciele Pharma and Addrenex Announce Initiation of Pivotal Phase III Trials for Clonicel for ADHD
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2007
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2007
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2007
Cortex Files AMPAKINE CX717 IND for ADHD
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 4 Sep 2007
Noven Provides Update on Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 4 Sep 2007
Shire Voluntarily Withdraws a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 4 Sep 2007
Transdermal Patch Growth Relying on Improved Designs, Enhanced Manufacturing Methods
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jul 2007
Shire's New ADHD Medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals to Market CLONICEL(R)
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2007
Shire Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2007
Noven & Shire to Develop New Transdermal Patch For ADHD
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 20 Jun 2007
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 May 2007
Study Suggests Strattera(R) Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2007
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
Shire Completes Acquisition of New River
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Apr 2007
Shire Successfully Completes Tender Offer for New River Shares
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2007
Shire Begins External Search for President of Successful Human Genetic Therapies Business, on Retirement of David Pendergast at the End of 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
UK Launch Expands Global Reach of FOSRENOL(R)
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Feb 2007
BioBehavioral Diagnostics Secures $8.5 Million Series A Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 27 Oct 2006
Study Suggests Strattera(R) Was Effective in Treating ADHD in Children and Adolescents With ADHD and Reading Disorders
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Study Suggests Strattera(R) was Effective in Treating ADHD in Children and Adolescents with ADHD and Reading Disorders
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Oct 2006
New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
Shire's DAYTRANA(TM), First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in Pharmacies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Positive Study Results for DAYTRANA(TM) (methylphenidate transdermal system) Presented at a Major Medical Meeting
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 May 2006
UCB Completes Mutual Recognition Procedure for Equasym(TM) XL
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 108

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 108 additional stories matching:
ADHD
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!